Brought to you by 
Series C leads to $56mm for Achaogen
Apr 2010
Executive Summary
Antibiotics developer Achaogen Inc. has raised $56mm in its Series C financing led by first-time backer Frazier Healthcare Ventures, which adds a board member and was joined by other new investor Alta Partners and returning shareholders 5AM Ventures, Arch Venture Partners, Domain Associates, Venrock Associates, Versant Ventures, and Wellcome Trust. The company will use some of the funds for a Phase II trial of its lead candidate ACHN490 for complicated urinary tract infections.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C leads to $56mm for Achaogen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice